Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

Michael Gundesen; Fredrik Schjesvold; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Slordahl; Jon Thor Asmussen; Hareth Nahi; Niels Abildgaard; Thomas Lund

doi:10.1016/S2152-2650(23)01577-X

Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

Michael Gundesen, Fredrik Schjesvold, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Slordahl, Jon Thor Asmussen, Hareth Nahi, Niels Abildgaard, Thomas Lund

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	OA-10
Journal	Clinical Lymphoma, Myeloma & Leukemia
Volume	23
Issue number	Suppl. 2
Pages (from-to)	S6-S7
ISSN	2152-2650
DOIs	https://doi.org/10.1016/S2152-2650(23)01577-X
Publication status	Published - Sept 2023
Event	20th International Myeloma Society Annual Meeting and Exposition - Megaron Athens International Conference Centre, Athen, Greece Duration: 27 Sept 2023 → 30 Sept 2023 https://www.myelomasociety.org/events/20th-ims-annual-meeting/

Conference

Conference	20th International Myeloma Society Annual Meeting and Exposition
Location	Megaron Athens International Conference Centre
Country/Territory	Greece
City	Athen
Period	27/09/2023 → 30/09/2023
Internet address	https://www.myelomasociety.org/events/20th-ims-annual-meeting/

Bibliographical note

Abstract No. OA-10

Access to Document

10.1016/S2152-2650(23)01577-X

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Gundesen, M., Schjesvold, F., Vangsted, A. J., Helleberg, C., Haukås, E., Silkjær, T., Teodorescu, E. M., Jensen, B. A., Slordahl, T., Asmussen, J. T., Nahi, H., Abildgaard, N., & Lund, T. (2023). Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple. Clinical Lymphoma, Myeloma & Leukemia, 23(Suppl. 2), S6-S7. Article OA-10. https://doi.org/10.1016/S2152-2650(23)01577-X

@article{09019f7929f74c648738ec7eeb6087de,

title = "Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple",

author = "Michael Gundesen and Fredrik Schjesvold and Vangsted, {Annette Juul} and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Teodorescu, {Elena Manuela} and Jensen, {Bo Amdi} and Tobias Slordahl and Asmussen, {Jon Thor} and Hareth Nahi and Niels Abildgaard and Thomas Lund",

note = "Abstract No. OA-10; 20th International Myeloma Society Annual Meeting and Exposition, IMS 2023 ; Conference date: 27-09-2023 Through 30-09-2023",

year = "2023",

month = sep,

doi = "10.1016/S2152-2650(23)01577-X",

language = "English",

volume = "23",

pages = "S6--S7",

journal = "Clinical Lymphoma, Myeloma & Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "Suppl. 2",

url = "https://www.myelomasociety.org/events/20th-ims-annual-meeting/",

}

Gundesen, M, Schjesvold, F, Vangsted, AJ, Helleberg, C, Haukås, E, Silkjær, T, Teodorescu, EM, Jensen, BA, Slordahl, T, Asmussen, JT, Nahi, H, Abildgaard, N & Lund, T 2023, 'Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple', Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. Suppl. 2, OA-10, pp. S6-S7. https://doi.org/10.1016/S2152-2650(23)01577-X

Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple. / Gundesen, Michael; Schjesvold, Fredrik; Vangsted, Annette Juul et al.
In: Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. Suppl. 2, OA-10, 09.2023, p. S6-S7.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

AU - Gundesen, Michael

AU - Schjesvold, Fredrik

AU - Vangsted, Annette Juul

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Teodorescu, Elena Manuela

AU - Jensen, Bo Amdi

AU - Slordahl, Tobias

AU - Asmussen, Jon Thor

AU - Nahi, Hareth

AU - Abildgaard, Niels

AU - Lund, Thomas

N1 - Abstract No. OA-10

PY - 2023/9

Y1 - 2023/9

U2 - 10.1016/S2152-2650(23)01577-X

DO - 10.1016/S2152-2650(23)01577-X

M3 - Conference abstract in journal

SN - 2152-2650

VL - 23

SP - S6-S7

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

IS - Suppl. 2

M1 - OA-10

T2 - 20th International Myeloma Society Annual Meeting and Exposition

Y2 - 27 September 2023 through 30 September 2023

ER -